Robbins Geller Announces Class Action Opportunity for Tempus AI Investors Facing Losses

In an important development for investors in Tempus AI, Inc. (NASDAQ: TEM), the law firm Robbins Geller Rudman & Dowd LLP has opened an opportunity for those who acquired shares during the designated Class Period, from August 6, 2024, to May 27, 2025. This announcement comes ahead of the rapidly approaching deadline on August 12, 2025, for potential lead plaintiffs interested in participating in the class action lawsuit. The lawsuit addresses allegations of significant fraud in relation to the company’s operations and financial disclosures.

Background of the Class Action Lawsuit

The lawsuit, filed in the Northern District of Illinois under the caption Shouse v. Tempus AI, Inc., accuses Tempus AI and its executives of breaching the Securities Exchange Act of 1934. The firm claims that the company's leadership made numerous misleading statements and failed to disclose critical information regarding the company's financial health. Notably, the suit asserts that Tempus AI inflated contract agreement values and engaged in questionable financial practices involving related party transactions that were non-binding and self-funded. These allegations suggest a pattern of deception that misrepresented the company's actual performance and viability.

Particularly concerning is the assertion that a joint venture with SoftBank Group Corporation raised significant red flags, prompting fears of capital manipulation in order to fabricate revenue figures for Tempus AI. Moreover, the acquisition of Ambry Genetics Corporation by Tempus AI is described as based on aggressive billing practices that could jeopardize the company’s sustainability if subjected to scrutiny. The controversy escalated when it was reported that AstraZeneca PLC had curtailed its financial commitments to Tempus AI through an obscure